Lawfulshare:

I have no inside information on SenoRX so I operate outside of that circle, however, I think its fairly safe assuption to say that Q3 "should" reflect much the same forward progress made in Q2 - - - - significantly higher revenue, gross profit improvement and positive cash flow. If the company shows positive progress in those three areas, I believe it will move the stock somewhat higher. I'm into SENO on a long term basis, and for me, that is 12 to 24 months - - - and it could be longer. I see it as a company that will more than holds it own to competition (Hologic). I fully expect they will take market share away from them going forward due to the fact they clearly have the best product line in this niche. The international market element here could provide a real boost to revenue in the next few years. As for the pending litigation with Hologic, its my belief the current share price more than discounts the impact of any negative news. The way I see it, the share price over the longer term should provide for a nice multi-bagger given some patience.

Cheers and good investing,
Retiredtechie/RT